8-K: Galectin Therapeutics Reports Positive NAVIGATE Trial Data

Galectin Therapeutics Inc. announced promising 18-month results from its NAVIGATE trial for Belapectin in MASH cirrhosis, showing a statistically significant reduction in the composite primary endpoint and new varices in the per-protocol population.

Summary

• Belapectin, a novel galectin-3 inhibitor, is being developed for MASH cirrhosis and portal hypertension, and as a combination therapy for cancer.
• The NAVIGATE trial, an 18-month study in MASH cirrhosis patients with portal hypertension but no varices at baseline, met its composite primary endpoint with a 2-sided p-value of 0.048 for the ITT population.
• In the per-protocol population, Belapectin 2 mg/kg reduced the incidence of new varices by 48.9% compared to placebo (10.3% vs 20.2%, p=0.04).
• Belapectin 2 mg/kg also showed a -8.4% mean change in Liver Stiffness Measurement (LSM) from baseline in the per-protocol population, compared to a +1.7% increase for placebo.
• Fewer subjects on Belapectin 2 mg/kg showed worsening in LSM (>30% or >5 kPa increase) compared to placebo (p=0.03).
• The drug maintained a clean safety profile with low discontinuation rates and no drug-related serious adverse events or Drug-Induced Liver Injury (DILI).
• An investigator-initiated Phase 1 study of Belapectin combined with pembrolizumab (Keytruda) in advanced cancers showed objective responses in 50% of metastatic melanoma and 33% of head and neck squamous cell carcinoma patients, with good tolerability.
• The company has filed an IND and received FDA approval to proceed for Head & Neck cancer.
• MASH cirrhosis represents a significant market opportunity with no FDA-approved treatment, with an estimated 1.7 million patients in the U.S. with compensated MASH cirrhosis and portal hypertension with no varices in 2024, and potential peak U.S. sales of $18 billion.

Sentiment

Score: 7

Explanation: The filing presents positive clinical trial results for Belapectin in MASH cirrhosis, meeting its primary composite endpoint and showing significant efficacy in the per-protocol population. The safety profile is clean, and the oncology program shows promise. However, some ITT endpoints for varices alone were not statistically significant, and the company acknowledges risks related to future funding and partnerships.

Positives

• NAVIGATE trial met its composite primary endpoint in the ITT population (p=0.048).
• Statistically significant reduction in new varices in the per-protocol population with Belapectin 2 mg/kg (48.9% reduction vs placebo, p=0.04).
• Belapectin 2 mg/kg demonstrated improvement in Liver Stiffness Measurement (LSM) and fewer subjects showed worsening in LSM (p=0.03).
• Clean safety profile with no drug-related serious adverse events or DILI.
• Encouraging clinical efficacy and safety observed in Phase 1 oncology trials combining Belapectin with Keytruda for metastatic melanoma and head and neck cancer.
• FDA Fast Track Designation for Belapectin.
• Patent protection for Belapectin through 2032.
• Significant unmet medical need and large market opportunity in MASH cirrhosis with no approved treatments, estimated potential peak U.S. sales of $18 billion.
• IND filed and FDA approval received to proceed with Head & Neck cancer trials.

Negatives

• Reduction in new varices in the ITT population (43.2% for 2mg vs placebo) was not statistically significant (p=0.139).
• Higher dropout rate (18.3% observed vs. 10% expected) in the NAVIGATE trial, mostly during COVID and the first four months.
• Lack of dose response observed at higher doses (4 mg/kg and 8 mg/kg in previous GT-026 trial), suggesting target-mediated drug disposition.
• Fewer subjects progressed to High-Risk ELF Category (ELF >= 13) in Belapectin 2mg was not statistically significant (p=0.09 vs placebo).

Risks

• Full analysis of NAVIGATE trial data may not produce positive data.
• Future phases or clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove time-consuming and costly.
• Plans regarding development, approval, and marketing of any drugs are subject to change at any time based on management and regulatory agencies' needs.
• Strategies and spending projections may change.
• Unsuccessful in developing partnerships with other companies or obtaining capital to complete clinical trials or further develop/fund future studies.
• Incurred operating losses since inception, and future success may be impacted by ability to manage costs and finance continuing operations.
• Actual events or results may differ materially from forward-looking statements.

Future Outlook

The company plans to seek FDA feedback on the NAVIGATE results by year-end and is actively pursuing partnership opportunities for Belapectin. It also intends to advance its oncology program, having received FDA approval to proceed with Head & Neck cancer trials in combination with Keytruda.

Management Comments

• Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies.
• Strategies and spending projections may change.
• We may be unsuccessful in developing partnerships with other companies or obtaining capital that would allow us to complete our clinical trials or further develop and/or fund any future studies or trials.
• To date, we have incurred operating losses since our inception, and our future success may be impacted by our ability to manage costs and finance our continuing operations.

Industry Context

The MASH cirrhosis market represents a significant unmet medical need with no FDA-approved treatments, positioning Belapectin as a potential first-in-class therapy. The estimated market opportunity for Belapectin in the U.S. is substantial, with potential peak sales of $18 billion. In oncology, combining Belapectin with checkpoint inhibitors like Keytruda aligns with a growing trend in cancer immunotherapy to overcome resistance and enhance efficacy, particularly in difficult-to-treat cancers like metastatic melanoma and head and neck squamous cell carcinoma.

Comparison to Industry Standards

• NAVIGATE enrolled the most advanced patients of recent MASH trials, requiring both MASH cirrhosis and portal hypertension, indicating a focus on a high-need patient population.
• The per-protocol population definition (18-month treatment + EGD) parallels completer biopsy definition in MASH trials, aligning with common industry practices for assessing treatment efficacy in liver diseases.
• Belapectin's low toxicity as a carbohydrate-based molecule, degraded by natural processes, offers a potentially favorable safety profile compared to other drug classes.
• The observed lack of dose response at higher doses of Belapectin, attributed to target-mediated drug disposition (TMDD), is a pharmacokinetic-pharmacodynamic (PK-PD) profile similar to that shown by monoclonal antibodies and interferon, suggesting a known biological phenomenon rather than a drug-specific issue.

Stakeholder Impact

• Shareholders: Positive clinical trial results and a clean safety profile could increase investor confidence and potentially lead to share price appreciation, especially if FDA feedback is favorable and partnerships are secured. However, risks related to future funding and the need for partnerships remain.
• Patients with MASH Cirrhosis: Belapectin offers a potential first-in-class treatment option for a disease with no FDA-approved therapies, potentially improving outcomes and quality of life, particularly for those with portal hypertension and no varices.
• Patients with Advanced Cancers: The encouraging results from the combination therapy with Keytruda could offer new treatment avenues for difficult-to-treat metastatic melanoma and head and neck cancers.
• Healthcare Providers: A new, effective, and safe treatment for MASH cirrhosis would provide a valuable tool for managing a growing patient population with high unmet needs.
• Regulatory Authorities (FDA): The company is engaging with the FDA for feedback on the NAVIGATE results, indicating ongoing regulatory interaction and potential for future approval pathways.

Next Steps

• Obtain FDA feedback on NAVIGATE results by year-end.
• Actively pursue partnership opportunities for Belapectin.
• Advance the oncology program for Head & Neck cancer following FDA approval to proceed.

Key Dates

Recommendation

While the NAVIGATE trial results are promising, particularly the statistically significant composite primary endpoint and the per-protocol varices reduction, the lack of statistical significance for varices alone in the ITT population introduces some ambiguity. The company also explicitly highlights the need for partnerships and potential capital raises to fund future development. Given the positive but mixed results and the acknowledged financial and partnership dependencies, a 'hold' recommendation is appropriate. Investors should await FDA feedback and further clarity on partnership developments before making more aggressive moves.

Keywords

Galectin Therapeutics, Belapectin, MASH Cirrhosis, Portal Hypertension, Galectin-3 Inhibitor, NAVIGATE Trial, Oncology, Cancer Immunotherapy, Keytruda, Pembrolizumab, Liver Fibrosis, Varices, FDA Fast Track, Clinical Trials, Biotechnology, Pharmaceuticals